Ovid Therapeutics (OVID) Current Assets (2016 - 2026)

Ovid Therapeutics (OVID) has reported Current Assets for 11 consecutive years, with $123.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Current Assets rose 193.7% year-over-year to $123.6 million; the trailing twelve-month figure through Jun 2026 stood at $123.6 million (up 193.7% YoY), and the FY2025 full-year result was $74.4 million, up 32.94% from the prior year.
• Current Assets fell to $123.6 million in Q2 2026 per OVID's latest filing, from $160.1 million in the prior quarter.
• Across five years, Current Assets topped out at $170.1 million in Q1 2022 and bottomed at $28.8 million in Q3 2025.
• Historically, Current Assets has averaged $99.5 million across 5 years, with a median of $97.7 million in 2023.
• The sharpest annual moves came in 2025 and 2026: Current Assets sank 56.21% in 2025, then surged 248.74% in 2026.
• Over 5 years, Current Assets stood at $131.4 million in 2022, then slipped by 16.58% to $109.6 million in 2023, then tumbled by 48.96% to $55.9 million in 2024, then surged by 32.94% to $74.4 million in 2025, then jumped by 66.22% to $123.6 million in 2026.
• According to Business Quant data, Current Assets over the past three periods registered $123.6 million, $160.1 million, and $74.4 million for Q2 2026, Q1 2026, and Q4 2025 respectively.